Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

HCATBullishCorporate Developmentsnews

High materiality7/10

Health Catalyst names CEO with large RSU grant and insider stake

Sep 14, 2026, 7:09 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Insider alignment via new CEO appointment with sizable RSUs can boost strategic execution expectations; near-term dilution risk may offset some upside.

AI summary

What happened, with direct paths to the underlying reporting

Health Catalyst appointed Simeon Kohl as CEO and President, granting 2.75 million RSUs under the 2026 Inducement Plan. Kohl also bought 59,000 shares at about $1.79, signaling alignment. The multi-year vesting and dilution risk may weigh near-term; execution will determine upside over the next 12-24 months.

Health Catalyst grants 2,747,385 RSUs to new CEO Simeon Kohl.
RSUs vest 915,975 on Sept 14, 2027; remaining vest in eight quarterly installments.
Grants under 2026 Employment Inducement Plan; Nasdaq Rule 5635(c)(4) compliance.
Appointment effective Sept 14, 2026; Kohl bought 59,000 shares around $1.79.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Health Catalyst names CEO with large RSU grant and insider stake

Health Catalyst (HCAT) Q1 Earnings Beat Estimates